Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cost of Revenue (2020 - 2025)

Insight Molecular Diagnostics' Cost of Revenue history spans 6 years, with the latest figure at $1.4 million for Q3 2025.

  • For Q3 2025, Cost of Revenue rose 32.89% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $6.1 million, up 242.06%, while the annual FY2024 figure was $3.9 million, 293.61% up from the prior year.
  • Cost of Revenue for Q3 2025 was $1.4 million at Insight Molecular Diagnostics, down from $1.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.3 million in Q4 2021 and bottomed at -$2.5 million in Q4 2022.
  • The 5-year median for Cost of Revenue is $846000.0 (2024), against an average of $1.0 million.
  • The largest annual shift saw Cost of Revenue crashed 175.82% in 2022 before it soared 5712.5% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $3.3 million in 2021, then plummeted by 175.82% to -$2.5 million in 2022, then soared by 94.22% to -$145000.0 in 2023, then surged by 1495.17% to $2.0 million in 2024, then tumbled by 31.49% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Cost of Revenue are $1.4 million (Q3 2025), $1.9 million (Q2 2025), and $806000.0 (Q1 2025).